Published in Ann Oncol on November 11, 2009
Current status of bevacizumab in advanced ovarian cancer. Onco Targets Ther (2013) 0.85
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. Invest New Drugs (2015) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Optimal two-stage designs for phase II clinical trials. Control Clin Trials (1989) 21.03
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst (2004) 2.79
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol (2007) 1.93
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol (2004) 1.50
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol (2005) 1.41
Can we now agree to use the same definition to measure response according to CA-125? J Clin Oncol (2004) 0.94
Clinical trials in ovarian carcinoma: study methodology. Ann Oncol (2005) 0.90
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol (2006) 0.88
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst (2009) 2.83
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol (1999) 2.80
Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett (1989) 2.69
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer (2009) 2.52
Isolation of a Pseudomonas stutzeri strain that degrades o-xylene. Appl Environ Microbiol (1987) 2.41
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Protein quality control along the route to the plant vacuole. Plant Cell (1997) 2.33
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer (2003) 2.20
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol (2000) 2.20
Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain (2002) 2.17
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol (1997) 2.17
[Results and fertility after conservative treatment of invasive epithelial ovarian cancer]. Gynecol Obstet Fertil (2002) 2.03
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol (2002) 2.00
Comparison of self-organizing maps classification approach with cluster and principal components analysis for large environmental data sets. Water Res (2007) 2.00
[Laparoscopic treatment of borderline ovarian tumor: analysis of 54 patients and clinical outcomes]. Gynecol Obstet Fertil (2005) 1.99
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (2000) 1.99
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol (1994) 1.97
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer (1995) 1.88
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol (2004) 1.85
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol (2007) 1.83
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst (1990) 1.81
Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res (2000) 1.81
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol (1996) 1.76
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer (2000) 1.74
Electroclinical, MRI and neuropathological study of 10 patients with nodular heterotopia, with surgical outcomes. Brain (2004) 1.73
Paclitaxel-induced neuropathy. Ann Oncol (1995) 1.65
Taxanes: a new class of antitumor agents. Cancer Invest (1995) 1.62
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol (1998) 1.60
Cloning of the genes for and characterization of the early stages of toluene and o-xylene catabolism in Pseudomonas stutzeri OX1. Appl Environ Microbiol (1996) 1.59
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs (1998) 1.56
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. Gynecol Oncol (2001) 1.51
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer (1999) 1.50
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.48
Penetration of benzene, toluene and xylenes contained in gasolines through human abdominal skin in vitro. Toxicol In Vitro (2006) 1.47
Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer (1992) 1.45
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer (1991) 1.44
[Initial or interval debulking surgery for advanced stage ovarian cancer: state-of-the-art. How to select patients?]. Gynecol Obstet Fertil (2005) 1.44
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.43
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer (2002) 1.43
Surgical intervention in relapsed ovarian cancer is beneficial: pro. Ann Oncol (2013) 1.42
[The treatment of liver metastases of colorectal tumors using intra-arterial fluorouracil via hepatic artery, administered with a completely implantable access system and a portable infusion pump]. Ned Tijdschr Geneeskd (1993) 1.40
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
[Modalities and limits of conservative treatment of adenocarcinoma in situ of the uterine cervix: analysis of nine cases and review of the literature]. Gynecol Obstet Fertil (2003) 1.37
Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol (2006) 1.36
Analysis of the gene cluster encoding toluene/o-xylene monooxygenase from Pseudomonas stutzeri OX1. Appl Environ Microbiol (1998) 1.36
Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer (2000) 1.35
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol (1987) 1.34
A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer (2010) 1.33
Ricin A chain without its partner B chain is degraded after retrotranslocation from the endoplasmic reticulum to the cytosol in plant cells. Proc Natl Acad Sci U S A (2001) 1.33
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol (1993) 1.32
Surgical treatment of drug-resistant nocturnal frontal lobe epilepsy. Brain (2006) 1.31
Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol (1998) 1.31
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med (1990) 1.29
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology (2003) 1.28
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer (2011) 1.27
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol (2010) 1.26
Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. Obstet Gynecol (1994) 1.26
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol (1997) 1.25
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. Cancer Treat Rep (1984) 1.25
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol (2008) 1.24
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol (2012) 1.23
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer (1996) 1.23
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol (2007) 1.22
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 1.22
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer (2002) 1.22
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol (1998) 1.21
Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst (1995) 1.21
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol (1995) 1.19
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother (1989) 1.19
Cheyne-Stokes breathing during sleep in patients with left ventricular heart failure. South Med J (1985) 1.17
Aerobic degradation of tetrachloroethylene by toluene-o-xylene monooxygenase of Pseudomonas stutzeri OX1. Nat Biotechnol (2000) 1.16
Multivariate classification and modeling in surface water pollution estimation. Anal Bioanal Chem (2007) 1.15